Reported revenue of $106,500 for the three months ended March 31, 2026, and $136,500 for the six months ended March 31, 2026. Net loss for the three months ended March 31, 2026, was $151,386, compared to $151,351 in the prior year period. Cash and cash equivalents increased to $327,270 as of March 31, 2026, up from $17,828 at September 30, 2025. The company maintains a significant accumulated deficit of $1,456,279. Operations are currently focused on the VOCAM Plus diagnostic technology for animal health.